Investigational drug · Phase 3
New of Niraparib
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Castration-Resistant Prostatic Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
9
Any phase or sponsor naming "New of Niraparib"
First trial start
2019
Jan 25, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "New of Niraparib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Castration-Resistant Prostatic Cancer
Approved drugs for the same conditions: Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "New of Niraparib" as an intervention, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate CancerPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03748641 · 765 participants · Start Jan 25, 2019 · Primary completion Oct 8, 2021
Drug: Niraparib; Abiraterone Acetate and 3 more · For: Castration-Resistant Prostatic Cancer
Sites: Homewood, Alabama; Phoenix, Arizona; Tucson, Arizona · 318 sites in all
- Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast CancerPivotal-lookingRecruiting
Nagoya City UniversityAcademic, hospital or other
NCT06535893 · 100 participants (planned) · Start Jul 30, 2024 · Primary completion Jun 30, 2027
Drug: TN; TN-1 · For: Breast Cancer
Sites: Nagoya, Japan
Mario Negri Institute for Pharmacological ResearchAcademic, hospital or other
NCT03891576 · 83 participants · Start Nov 13, 2019 · Primary completion Aug 31, 2024
Drug: Niraparib · For: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma
Sites: Berlin, Germany; Dresden, Germany; Essen, Germany · 12 sites in all
Tesaro, Inc.GSK (GSK)
NCT03574779 · 77 participants · Start Nov 15, 2018 · Primary completion Jun 28, 2024
Drug: Niraparib; TSR-042 and 3 more · For: Ovarian Neoplasms
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 28 sites in all
Tesaro, Inc.GSK (GSK)
NCT03307785 · 60 participants · Start Oct 12, 2017 · Primary completion Feb 26, 2020
Drug: Niraparib; TSR-042 and 5 more · For: Neoplasms; Metastatic Cancer; Advanced Cancer and 4 more
Sites: Scottsdale, Arizona; Encinitas, California; San Marcos, California · 8 sites in all
GlaxoSmithKlineGSK (GSK)
NCT04641247 · 37 participants (planned) · Start Apr 16, 2021 · Primary completion Dec 28, 2026
Drug: Niraparib · For: Ovarian Neoplasms; Breast Neoplasms
Sites: Tucson, Arizona; Encinitas, California; Los Angeles, California · 25 sites in all
NRG OncologyAcademic, hospital or other
NCT04037254 · 22 participants · Start Oct 8, 2019 · Primary completion Jul 1, 2024
Drug: Gonadotrophin Releasing Hormone; Niraparib · For: Prostate Adenocarcinoma; Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8 and 4 more
Sites: Gilbert, Arizona; Tucson, Arizona; Duarte, California · 95 sites in all
University of PennsylvaniaAcademic, hospital or other
NCT04221061 · 3 participants · Start Feb 20, 2020 · Primary completion Jun 10, 2024
Drug: 18F-FluorThanatrace · For: Glioblastoma
Sites: Philadelphia, Pennsylvania
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Castration-Resistant Prostatic Cancer
- OpevesostatMK-5684, ODM-208Phase 37 trials
Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.